A Phase 1, Randomized, Controlled, Observer-blinded Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Healthy Adults Aged 18 to 49 Years

Inclusion criteria

• Male or female adults 18 to 49 years of age.
• Healthy adults determined by medical history, physical examination, laboratory screening, and clinical judgment to be eligible for the study.
• Negative serum pregnancy test for all female subjects who are of childbearing potential.

Exclusion criteria

• Baseline laboratory test results outside of the normal reference range considered clinically significant.
• History of severe adverse reaction and/or severe allergic reaction (eg, anaphylaxis) associated with a vaccine.
• History of culture-proven invasive disease caused by S pneumoniae.
• Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
• Vaccination with diphtheria-, pertussis-, or tetanus-containing vaccine(s) from 12 months before investigational product administration, or planned receipt through study participation.
• Male subjects and female subjects of childbearing potential who are unwilling or unable to use a highly effective method of contraception as outlined in this protocol for the duration of the study participation and for at least 6 months after the last dose of investigational product.